Krystal Biotech, Inc. (KRYS)
NASDAQ: KRYS · IEX Real-Time Price · USD
177.20
+3.03 (1.74%)
At close: Mar 27, 2024, 4:00 PM
178.50
+1.30 (0.73%)
After-hours: Mar 27, 2024, 6:42 PM EDT

Krystal Biotech Balance Sheet

Millions USD. Fiscal year is Jan - Dec.
Year 20232022202120202019201820172016
Cash & Equivalents
358.33161.9341.25268.27187.51103.6749.591.92
Short-Term Investments
173.85217.2796.852.996.178.0900
Cash & Cash Equivalents
532.18379.17438.1271.26193.69111.7649.591.92
Cash Growth
40.35%-13.45%61.50%40.05%73.30%125.37%2478.84%-
Receivables
42.040000000
Inventory
6.990000000
Other Current Assets
6.714.614.173.82.20.890.320.25
Total Current Assets
587.91383.78442.27275.06195.88112.6549.912.17
Property, Plant & Equipment
168.23169.73119.5834.1711.183.010.20.01
Long-Term Investments
61.954.6264.3700.5000
Other Long-Term Assets
0.260.320.071.611.460.4500
Total Long-Term Assets
230.45174.67184.0335.7913.143.470.20.01
Total Assets
818.36558.45626.3310.84209.02116.1250.112.18
Accounts Payable
4.133.988.42.111.020.890.190.04
Current Debt
1.471.561.040.640.48000
Other Current Liabilities
27.4923.3116.312.711.831.710.450
Total Current Liabilities
33.0928.8525.7415.453.332.60.640.04
Long-Term Debt
6.627.376.983.312.78001.84
Other Long-Term Liabilities
000000.2900.01
Total Long-Term Liabilities
6.627.376.983.312.780.2901.85
Total Liabilities
39.7136.2232.7218.766.112.890.641.89
Total Debt
8.098.938.023.953.26001.84
Debt Growth
-9.39%11.33%103.35%20.97%----
Retained Earnings
-269.83-280.76-140.78-71.21-39.05-19.96-9.07-1.15
Comprehensive Income
0.64-0.73-0.160.010.01000
Shareholders' Equity
778.64522.23593.58292.08202.91113.2349.470.29
Net Cash / Debt
524.08370.24430.07267.32190.42111.7649.590.08
Net Cash / Debt Growth
41.55%-13.91%60.89%40.38%70.38%125.37%61888.75%-
Net Cash Per Share
18.8814.5219.3814.2311.989.989.250.09
Working Capital
554.82354.93416.53259.61192.55110.0549.272.13
Book Value Per Share
28.6820.4926.7415.5512.7610.119.230.33
Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).